Cash and cash equivalents as of September 30, 2024, were $6.0 million. As noted above, the Company completed a registered public offering on October 30, 2024 that yielded net proceeds to the Company of approximately $17.7 million, after deducting placement agent fees and other estimated offering expenses.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNPR:
- Monopar Therapeutics Closes $19.2 Million Stock Offering
- Monopar Therapeutics 1.16M share Spot Secondary priced at $16.25
- Monopar Therapeutics announces common stock offering, no amount given
- Monopar Therapeutics Secures License for Wilson Disease Treatment
- Monopar Therapeutics enters agreement with Alexion, AstraZeneca Rare Disease